Close

Vertex Pharma (VRTX) Announces ORKAMBI Phase 3 Met Primary Endpoint in Children with CF

November 7, 2016 8:32 AM EST Send to a Friend
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced the results of a Phase 3 study of ORKAMBI (lumacaftor/ivacaftor) in children with cystic ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login